ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

European contractors land deals in the U.S.

by Rick Mullin
January 8, 2018 | APPEARED IN VOLUME 96, ISSUE 2

[+]Enlarge
Credit: Siegfried
Siegfried will manufacture for Keryx at this facility in Pennsville, N.J.
Credit: Siegfried
Siegfried will manufacture for Keryx at this facility in Pennsville, N.J.

Two European manufacturers of active pharmaceutical ingredients have signed supply contracts with U.S. biotech firms. France’s Novasep was selected by Tetraphase Pharmaceuticalsto manufacture eravacycline, an antibiotic in Phase III development for life-threatening infections. Novasep has supplied early-stage clinical quantities since 2014. Meanwhile, the Swiss contractor Siegfried will supply Keryx Biopharmaceuticals with ferric citrate, the active ingredient in the iron deficiency drug Auryxia. Keryx announced a similar agreement last month with the Canadian firm BioVectra.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment